Stealth BioTherapeutics OverviewTrack Stealth BioTherapeutics's gross profit ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2022
Trailing 12 months ending Mar 31, 2022
As of the most recent data (March 2022), MITO shows a gross profit of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MITO's gross profit is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Stealth BioTherapeutics is outperforming or lagging.
The Healthcare sector average gross profit is about $67B. Stealth BioTherapeutics is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how MITO stacks up against individual peers as well.
Tracking MITO's gross profit over time shows whether Stealth BioTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this gross profit page, Stockcircle has Stealth BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $0) with ownership activity and broader fundamentals.
